Diligence memo · auto-generated · as of July 2, 2026
Kv Pharmaceutical Co /De/
Kv Pharmaceutical Co /De/ looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Kv Pharmaceutical Co /De/ operates in Pharmaceuticals, based in Chesterfield.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Kv Pharmaceutical Co /De/ has raised $526M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $261M on 2013-06-06.
Most recent recorded round closed around 2013-06-06.
Valuation (modeled)modeled
Provath models Kv Pharmaceutical Co /De/ at approximately $9.2B (range $1.2B–$20.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.61× the median modeled value of Series D+ Pharmaceuticals companies in 2013–2015 (6 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 13.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1242.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Clovis Oncology, Inc., Opko Health, Inc., Horizon Pharma, Inc., HLS Therapeutics Inc., Biotie Therapies Corp..
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.